Naturalistic evaluation of entacapone in patients with signs and symptoms of L-dopa wearing-off

References

• Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001;56 (Suppl 5):1-88
   Google Scholar
• Miyasaki JM, Martin W, Suchowersky O, et al. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review [Report of the Quality Standards Subcommittee of the American Academy of Neurology]. Neurology 2002;58:11-7
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson's disease. A randomized controlled study. J Am Med Assoc 2000;248:1931-8
   Google Scholar
• Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000;47 (Suppl 1):2-11
   Google Scholar
• Lang AP, Lozano AE. Parkinson's disease. New Engl J Med 1998;339:1044-53
   PubMed Web of Science ®Google Scholar
• Koller WC, Tse W. Unmet medical needs in Parkinson's Disease. Neurology 2004;62 (Suppl 1):S1-8
   Google Scholar
• Grace A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 1991;41:1-24
   PubMed Web of Science ®Google Scholar
• Onn P, West AR, Grace AA. Dopamine-mediated regulation of striatal neuronal and network interactions. Trends Neurosci 2000;23 (Suppl):48-56
   PubMedGoogle Scholar
• Spenser SE, Wooten GF. Altered pharmacokinetics of L-dopa metabolism in rat striatum deprived of dopaminergic innervation. Neurology 1984;34:1105-8
   PubMed Web of Science ®Google Scholar
• Ahlskog JE, Muenter MD. Frequency of levodopa related dyskinesias and motor fluctuations as estimated from cumulative literature. Mov Disord 2001;16:448-58
   PubMed Web of Science ®Google Scholar
• Chase TN, Baronti F, Fabbrini G, et al. Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Neurology 1989;39 (Suppl 2):7-10
   PubMedGoogle Scholar
• Olanow CW, Schapira AHV, Rascol O. Continuous dopaminergic stimulation in the early treatment of PD. Trends Neurosci 2000;23 (Suppl):117-26
   Google Scholar
• Keränen T, Gordin A, Harjola VP, et al. The effect of catechol-O-methyltransferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 1993;16:145-56
   PubMed Web of Science ®Google Scholar
• Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913-9
   PubMed Web of Science ®Google Scholar
• Brooks DJ, Sagar H, the UK-IRISH Entacapone Study Group. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease. A randomised, placebo-controlled, double-blind six-month study. J Neurol Neurosurg Psychiatry 2003;74:1064-72
   Google Scholar
• Rinne UK, Larsen JP, Siden A, et al. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology 1998;51:1309-14
   PubMed Web of Science ®Google Scholar
• Poewe W, Deuschl G, Gordin A, et al. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a six-month randomised placebo-controlled double-blind study in Germany and Austria (CELOMEN study). Acta Neurol Scand 2002;105:245-55
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997;42:747-55
   PubMed Web of Science ®Google Scholar
• Olanow CW, Kieburtz K, Stern M, et al. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol 2004;61:1563-8
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals Canada, Inc. Comtan Prescribing Information. Revised December 1, 2006
   Google Scholar
• Jenkinson C, Fitzpatrick R, Peto V, et al. The PDQ-8: development and validation of a short-form Parkinson's disease questionnaire. Psychol Health 1997;12:805-14
   Web of Science ®Google Scholar
• Fahn SE. Unified Parkinson's Disease Rating Scale. In: Fahn S, ed. Recent developments in Parkinson's disease. Florham Park (NJ): MacMillan Healthcare Information; 1987. p.153-63
   Google Scholar
• Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005;62:241-8
   PubMed Web of Science ®Google Scholar